CliffBio
biologic

Spikevax

COVID-19 Vaccine, mRNA

Loss of exclusivityJuly 2037projected — 12-year biologic exclusivity estimate
CompanyModernaTX, Inc.

Drug detail

Brand nameSpikevax
Active ingredientCOVID-19 Vaccine, mRNA
Strength25UG/0.25mL
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 2025
Marketing statusRx

More from ModernaTX, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Spikevax patent cliff — loss of exclusivity July 2037 | CliffBio